Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy for second-line and above extensive-stage small cell lung cancer
ChiCTR2100044300Phase 2Recruiting
- Sponsor
- Heilongjiang Provincial Hospital
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in small cell lung cancer (SCLC), sponsored by Heilongjiang Provincial Hospital. Primary endpoint: Objective response rate (ORR). Started Mar 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100044300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044300.